Harbour BioMed Enters Global Strategic Collaboration with Otsuka to Advance BCMAxCD3 Bispecific T-Cell Engagers
Under the terms of the agreement, Otsuka is granted an exclusive license to develop, manufacture, and commercialize HBM7020, a BCMAxCD3 bispecific T-cell engager globally, excluding Greater China (Mainland China, Hong Kong, Macau and Taiwan). In return, Harbour BioMed will receive a total of $47 million in upfront and near-term payments. The company is also eligible for additional payments of up to $623 million upon the achievement of specified development and commercial milestones, as well as tiered royalties on future net sales. This strategic collaboration establishes a foundation for potential future partnerships between the two companies in the T-cell engager area.
'We are delighted to collaborate with Otsuka, a global healthcare leader renowned for its innovative approach to addressing unmet medical needs,' said Dr. Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed. 'This collaboration underscores the strength of Harbour BioMed's proprietary Harbour Mice® and HBICE® technology platforms, which enable the rapid development of fully human bispecific antibodies with optimized safety and efficacy profiles. By leveraging our unique capabilities, we are well-positioned to advance next-generation biotherapeutics that can make a meaningful difference in patients' lives worldwide.'
Makoto Inoue, President and Representative Director of Otsuka Pharmaceutical, noted, 'Otsuka is expanding our development pipeline in the autoimmune disease field by leveraging the antibody drug platform of our subsidiary Visterra, and the small molecule drug discovery platform of our subsidiary Jnana. HBM7020 is expected to demonstrate efficacy in a broad range of autoimmune diseases in which B cells play a major role in disease pathogenesis, and we hope to contribute further to the field of specialized autoimmune diseases and thereby benefit patients.'
About HBM7020
HBM7020 is a BCMAxCD3 bispecific antibody generated using Harbour BioMed's fully human HBICE® bispecific technology and Harbour Mice® platform. It is designed to crosslink target cells and T cells by binding to BCMA and CD3 on the cell surface, leading to potent T cell activation and targeted cell elimination. By incorporating dual anti-BCMA binding sites for enhanced cell targeting and monovalent-optimized CD3 activity to minimize cytokine release syndrome (CRS), HBM7020 has demonstrated potent cytotoxicity with broad therapeutic potential in both immunological and oncological diseases. In August 2023, HBM7020 obtained IND clearance from the National Medical Products Administration (NMPA) to commence a Phase I trial for cancer in China.
About Harbour BioMed
Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology. The company is building a robust and differentiated pipeline through internal R&D capabilities, strategic global collaborations in co-discovery and co-development, and selective acquisitions.
Harbour BioMed's proprietary antibody technology platform, Harbour Mice®, generates fully human monoclonal antibodies in both the conventional two heavy and two light chain (H2L2) format and the heavy chain-only (HCAb) format. Building upon HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) bispecific antibody technology enables tumor-killing effects that traditional combination therapies cannot achieve. Additionally, the HCAb-based bispecific immune cell antagonist (HBICATM) technology empowers the development of innovative biologics for immunological and inflammatory diseases. By integrating Harbour Mice®, HBICE®, and HBICATM with a single B-cell cloning platform, Harbour BioMed has built a highly efficient and distinctive antibody discovery engine for developing next-generation therapeutic antibodies. For more information, please visit www.harbourbiomed.com .
About Otsuka Pharmaceutical Co., Ltd.
Otsuka Pharmaceutical Co., Ltd. is a total healthcare company that focuses on each individual's potential to enhance their well-being. Our medical-related business provides treatments and diagnostics for both physical and mental health. Our nutraceutical business supports daily health maintenance and improvement. Otsuka's unique products and services are based on scientific evidence, under the guidance of our corporate philosophy: Otsuka-people creating new products for better health worldwide.
For further information, please visit www.otsuka.co.jp/en/
View original content to download multimedia: https://www.prnewswire.com/news-releases/harbour-biomed-enters-global-strategic-collaboration-with-otsuka-to-advance-bcmaxcd3-bispecific-t-cell-engagers-302487815.html
SOURCE Harbour BioMed
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
High Growth Tech Stocks In Asia Featuring Ningbo Yunsheng And Two More
As global markets continue to navigate a complex landscape, the Asian tech sector is capturing attention with its dynamic growth potential amidst mixed economic signals. In this context, identifying promising stocks involves looking for companies that demonstrate resilience and innovation, such as Ningbo Yunsheng and others that thrive despite broader market fluctuations. Name Revenue Growth Earnings Growth Growth Rating Suzhou TFC Optical Communication 30.19% 29.63% ★★★★★★ Shengyi Electronics 22.99% 35.16% ★★★★★★ Range Intelligent Computing Technology Group 27.31% 28.63% ★★★★★★ Shanghai Huace Navigation Technology 24.44% 23.48% ★★★★★★ PharmaResearch 26.50% 29.34% ★★★★★★ eWeLLLtd 24.95% 24.40% ★★★★★★ Global Security Experts 20.56% 28.04% ★★★★★★ CARsgen Therapeutics Holdings 81.53% 96.08% ★★★★★★ Marketingforce Management 26.39% 112.30% ★★★★★★ JNTC 55.45% 94.52% ★★★★★★ Click here to see the full list of 478 stocks from our Asian High Growth Tech and AI Stocks screener. We'll examine a selection from our screener results. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Ningbo Yunsheng Co., Ltd. focuses on the research, development, manufacture, and sale of rare earth permanent magnet materials in China with a market capitalization of CN¥12.67 billion. Operations: The company generates revenue primarily from the sale of Neodymium Iron Boron materials, totaling CN¥5.14 billion. Ningbo Yunsheng's recent pivot into profitability, with a net income of CN¥95.08 million from a prior loss, underscores its resilience and adaptability in the tech sector. This turnaround is highlighted by an impressive annual revenue growth rate of 17.8% and even more robust earnings growth at 39.8% per year, outpacing the broader Chinese market's average. The firm's commitment to innovation is evident from its R&D investments, ensuring it stays relevant amidst rapid technological advancements. With these strong financials and strategic focus on research and development, Ningbo Yunsheng appears well-positioned for sustained growth in Asia's competitive high-tech landscape. Click here and access our complete health analysis report to understand the dynamics of Ningbo Yunsheng. Explore historical data to track Ningbo Yunsheng's performance over time in our Past section. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Beijing Zhong Ke San Huan High-Tech Co., Ltd. operates in the high-tech industry with a market cap of CN¥14.79 billion. Operations: Beijing Zhong Ke San Huan High-Tech Co., Ltd. specializes in the high-tech sector, focusing on advanced materials and technology solutions. The company generates revenue through its diverse product offerings, catering to various industrial applications. Beijing Zhong Ke San Huan High-Tech has demonstrated a notable turnaround, with its first-quarter net income reaching CN¥13.49 million, a significant recovery from the previous year's loss. This improvement is anchored by robust earnings growth of 43.9% annually and an impressive revenue increase of 19.9% per year, signaling strong market demand and operational efficiency. Despite facing challenges like a recent dividend cut to CN¥0.20 per share, the company's strategic focus on R&D—evident from substantial investments—positions it well within Asia's dynamic tech landscape to leverage emerging technological trends effectively. Click to explore a detailed breakdown of our findings in Beijing Zhong Ke San Huan High-Tech's health report. Gain insights into Beijing Zhong Ke San Huan High-Tech's past trends and performance with our Past report. Simply Wall St Growth Rating: ★★★★★☆ Overview: Pansoft Company Limited offers management information solutions and IT integrated services for large enterprises in China, with a market cap of CN¥5.34 billion. Operations: Pansoft specializes in delivering management information solutions and IT integrated services to large enterprises across China. The company focuses on leveraging its expertise to support enterprise-level clients with tailored technological solutions. Pansoft, amidst a dynamic phase of corporate restructuring, has recently seen significant changes including amendments to its articles of association and adjustments in its registered capital, reflecting a strategic pivot aimed at enhancing governance and operational flexibility. Despite experiencing a downturn with a net loss of CN¥13.95 million in the first quarter of 2025 from a prior profit, the company's aggressive approach towards R&D investment aligns with its long-term vision to stabilize and eventually expand within the high-tech sector in Asia. Notably, Pansoft's revenue growth forecast at 21.1% annually surpasses China's market average by nearly 9%, coupled with an anticipated earnings surge of 32.2% per year—outpacing the broader market's expectation by almost 9%. This robust financial trajectory, backed by substantial reinvestment in innovation and technology development, positions Pansoft to potentially leverage emerging tech trends effectively despite current volatility. Delve into the full analysis health report here for a deeper understanding of Pansoft. Understand Pansoft's track record by examining our Past report. Delve into our full catalog of 478 Asian High Growth Tech and AI Stocks here. Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up. Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SHSE:600366 SZSE:000970 and SZSE:300996. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
High Growth Tech Stocks in Asia Featuring Vobile Group and Two Others
As global markets continue to navigate a landscape marked by mixed economic signals, with U.S. small-cap indexes like the S&P MidCap 400 and Russell 2000 showing notable gains, investors are closely watching Asian tech stocks for potential growth opportunities. In this dynamic environment, identifying high-growth tech stocks in Asia requires a keen understanding of market trends and economic indicators that can influence performance, such as innovation capabilities and adaptability to shifting trade policies. Name Revenue Growth Earnings Growth Growth Rating Shengyi Electronics 22.99% 35.16% ★★★★★★ Fositek 28.67% 35.10% ★★★★★★ Shanghai Huace Navigation Technology 24.44% 23.48% ★★★★★★ Range Intelligent Computing Technology Group 27.31% 28.63% ★★★★★★ eWeLLLtd 24.95% 24.40% ★★★★★★ PharmaResearch 25.04% 26.89% ★★★★★★ Global Security Experts 20.56% 28.04% ★★★★★★ CARsgen Therapeutics Holdings 81.05% 87.21% ★★★★★★ Marketingforce Management 26.39% 112.30% ★★★★★★ JNTC 55.45% 94.52% ★★★★★★ Click here to see the full list of 487 stocks from our Asian High Growth Tech and AI Stocks screener. Let's review some notable picks from our screened stocks. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Vobile Group Limited is an investment holding company that offers software as a service for digital content asset protection and transactions across the United States, Mainland China, and internationally, with a market cap of HK$8.46 billion. Operations: The company generates revenue primarily through its SaaS offerings for digital content asset protection and transactions, amounting to HK$2.40 billion. Vobile Group's strategic moves, including a recent alliance with Shanghai Film Group and several equity offerings totaling over HKD 1 billion, underscore its aggressive expansion in digital cultural content. This growth trajectory is supported by a notable 23% revenue increase in Q1 2025 compared to the previous year, with mainland China revenues up by 21%. The company's commitment to innovation is evident from its investment in R&D, crucial for staying competitive in the fast-evolving tech landscape. Despite challenges like lower than industry average return on equity projections (13.6%), Vobile's earnings are expected to surge by 28.55% annually, outpacing the Hong Kong market forecast of 10.3%. This blend of strategic partnerships and robust financial performance positions Vobile as a dynamic player in Asia's tech scene, albeit with areas requiring careful navigation to maintain momentum. Get an in-depth perspective on Vobile Group's performance by reading our health report here. Learn about Vobile Group's historical performance. Simply Wall St Growth Rating: ★★★★★☆ Overview: Zhejiang Top Cloud-agri Technology Co., Ltd. operates in the agricultural technology sector, focusing on innovative solutions and has a market capitalization of CN¥7.96 billion. Operations: Zhejiang Top Cloud-agri Technology Co., Ltd. specializes in the agricultural technology sector, offering innovative solutions to enhance farming practices. The company generates revenue through its advanced technological products and services designed for agriculture, contributing significantly to its market presence. Zhejiang Top Cloud-agri Technology, despite its niche focus on agricultural tech, is making significant strides in the high-growth tech sector in Asia. With a robust 26.4% annual revenue growth and an even more impressive projected earnings increase of 29% per year, the company is outperforming many regional counterparts. Recent affirmations of dividends at CNY 5.865 per 10 shares highlight financial stability and shareholder confidence. Additionally, amendments to its bylaws reflect a dynamic approach to governance, aligning with its innovative drive in deploying advanced technologies for agricultural enhancements. This strategic positioning not only underscores its commitment to growth but also enhances its potential in a critical sector that bridges technology with sustainable farming practices. Dive into the specifics of Zhejiang Top Cloud-agri TechnologyLtd here with our thorough health report. Evaluate Zhejiang Top Cloud-agri TechnologyLtd's historical performance by accessing our past performance report. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Future Corporation is a Japanese company specializing in IT consulting and services, with a market cap of ¥201.54 billion. Operations: The company generates revenue primarily through its IT Consulting & Services segment, which includes package software and services, contributing ¥63.38 billion. Business Innovation adds another ¥8.85 billion to the total revenue stream. Future Corporation is positioning itself as a resilient contender in Asia's tech industry, with its board recently resolving to utilize treasury stock for strategic equity plans, signaling confidence in its financial health and governance. This move coincides with an uptick in dividend payouts to JPY 23.00 per share, reflecting a robust financial strategy amidst a forecasted annual revenue growth of 9.9% and earnings growth of 13.9%. Notably, the company's R&D commitment is underscored by significant investments aimed at fostering innovation and maintaining competitive advantage in a rapidly evolving market landscape. These strategic decisions are set against a backdrop of solid performance metrics such as an expected operating profit of JPY 16,050 million for the fiscal year ending December 2025, illustrating Future's adept navigation through tech sector challenges while capitalizing on growth opportunities. Unlock comprehensive insights into our analysis of Future stock in this health report. Gain insights into Future's historical performance by reviewing our past performance report. Gain an insight into the universe of 487 Asian High Growth Tech and AI Stocks by clicking here. Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance. Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SEHK:3738 SZSE:301556 and TSE:4722. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
CARsgen Successfully Defends Its GPC3 CAR-T Patent at the EPO
SHANGHAI, July 13, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: a company focused on developing innovative CAR T-cell therapies, announces a favorable outcome in opposition proceedings before the European Patent Office (EPO) concerning its European patent EP3445407, which covers its GPC3-targeted CAR-T cell therapy. On July 3, 2025, a U.S.-based biotechnology — the sole appellant among the original two opponents — formally withdrew its appeal against the EPO Opposition Division's earlier decision to maintain the patent. This withdrawal renders the EPO's decision final and binding for the opponents, effectively concluding their part in the opposition process. The patent was granted by the EPO in 2022 and opposed by two parties in 2023. Following oral proceedings, the EPO Opposition Division issued a decision to maintain the patent in amended form, upholding key claims related to the use of GPC3 CAR-T cell therapy following cyclophosphamide and fludarabine lymphodepletion pretreatment, in the treatment of liver cancer, lung cancer, ovarian cancer, breast cancer, gastric cancer, and thyroid cancer. Following the decision, only one opponent filed an appeal within the allowable period. That appeal has now been withdrawn. Under EPO procedures, the opponents or any other third party can no longer challenge the patent at the EPO. This development further reinforces CARsgen's intellectual property position in the field of GPC3-targeted CAR-T therapies, a promising and innovative approach for the treatment of solid tumors. About CARsgen Therapeutics Holdings Limited CARsgen is a biopharmaceutical company focusing on developing innovative CAR T-cell therapies to address the unmet clinical needs including but not limited to hematologic malignancies, solid tumors and autoimmune diseases. CARsgen has established end-to-end capabilities for CAR T-cell research and development covering target discovery, preclinical research, product clinical development, and commercial-scale production. CARsgen has developed novel in-house technologies and a product pipeline with global rights to address challenges faced by existing CAR T-cell therapies. Efforts include improving safety profile, enhancing the efficacy in treating solid tumors, and reducing treatment costs, etc. CARsgen's mission is to be a global biopharmaceutical leader that provides innovative and differentiated cell therapies for patients worldwide and makes cancer and other diseases curable. Forward-looking Statements All statements in this press release that are not historical fact or that do not relate to present facts or current conditions are forward-looking statements. Such forward-looking statements express the Group's current views, projections, beliefs and expectations with respect to future events as of the date of this press release. Such forward-looking statements are based on a number of assumptions and factors beyond the Group's control. As a result, they are subject to significant risks and uncertainties, and actual events or results may differ materially from these forward-looking statements and the forward-looking events discussed in this press release might not occur. Such risks and uncertainties include, but are not limited to, those detailed under the heading "Principal Risks and Uncertainties" in our most recent annual report and interim report and other announcements and reports made available on our corporate website, No representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on, any projections, targets, estimates or forecasts contained in this press release. Contact CARsgen For more information, please visit View original content to download multimedia: SOURCE CARsgen Therapeutics
